Welcome & Introductions
Meeting Chairs: Claire Harrison & Naveen Pemmaraju 

Session 1: Biology
Chairs: Ronald Hoffman & Claire Harrison

• Calreticulin biology and targeting: Bethan Psaila
• Genomics of MPN – Updates in 2024: Olatoyosi Odenike
• Pathophysiology of progression: Ronald Hoffman
• CHIP, JAK2 and MPN: David Steensma

Panel discussion

Session 2 PV and ET
Chairs: Andrew Kuykendall & Kristen Pettit

• New options for the management of ET but do all patients need treatment: Kristen Pettit
• Current data regarding young MPN patients: Lucia Masarova
• Should we still use HU first line for PV patients? Andrew Kuykendall

Panel discussion

Break

Session 3: Endpoint discussion in MPNs
Chairs: Ruben Mesa & Claire Harrison

• Should SVR35 still be the gold standard in MF, and if not, what are the options?: John Mascarenhas
• Is there a ceiling in assessing symptom response for MF/ MPNs?: Ruben Mesa
• The future of clinical trials in MF: an industry perspective: David Steensma
• Disease modification as an endpoint in PCV/ET: Jan Bewersdorf

Panel discussion

Session 4: CMML and BPDCN
Chairs: Michael Savona & John Bennett     

• RASopathies, key features of RAS family-mutated CMML and treatment options: Mrinal Patnaik
• The special case of MDS/MPN-RS-T: Valeria Santini
• BPDCN: Naveen Pemmaraju

Lunch

Session 5: Unmet needs in Myelofibrosis
Chairs: Naveen Pemmeraju & TBC

• Important updates with combination therapy in MF in first line I: Pelabrasib: Claire Harrison
• Important updates in frontline combo MF II: BCLxL: navitoclax & selinexor: Naveen Pemmaraju
• New options for management of thrombocytopenia and anemia in MF: Aaron Gerds
• Pre-fibrotic myelofibrosis: Abdulraheem Yacoub

Panel discussion

Session 6: Accelerated disease and transplant
Chairs: John Mascarenhas & David Steensma

• How to define accelerated phase MPN: Lucia Masarova
• Transplantation for MF in chronic and accelerated phase: Donal McLornan
• Pathologist features of MPN in evolution: Mina Xu

Panel discussion

 

Break

Session 7: Targeting the iron pathway from anemia to polycythemia
Chairs: Aaron Gerds & Donal McLornan

• Utilizing momelotinib to treat anemia in MPN: Claire Harrison
• Treating anemia in in MF with luspatercept: Aaron Gerds
• Controlling erythrocytosis with rusfertide in PV: Ronald Hoffman
• Clinical experience targeting hepcidin pathways in PV: Marina Kremyanskaya

Panel discussion

Session 8: Overlaps with MDS
Chairs: Claire Harrison & Daniel Wiseman

• Targeting telomerase in MPN and MDS: John Mascarenhas
• What should MPN learn from MDS?: Matteo Della Porta
• Approaches from the MDS/MPN IWG: ABNL MARRO and beyond: Daniel Wiseman

Panel discussion

Conclusions & end of Day 1

Introduction & meeting objectives
Chair: Amer Zeidan

Session 1: New trends in CHIP/CCUS
Chairs: Michael Savona & Uma Borate

• The SEARCH CONSORTIUM: Looking for Answers in CHIP And CCUS: Zhuoer Xie
• Clonal hematopoiesis and transplantation outcomes: Coleman Lindsley
• Should CCUS be considered as lower risk MDS?: Lachelle Weeks
• Clonal hematopoiesis and bone marrow failure disorders; Austin Kulasekararaj
• Putting it all together: Michael Savona

Panel discussion

Keynote talk:

Leveraging the icMDS combined database to answer timely and important questions on classification and risk stratification in MDS: Matteo Della Porta

Break

Session 2: Rising STARs session: MDS in special populations
Chairs: Amer Zeidan & Stephen Nimer

• DDX41-mut MDS/AML: Carmelo Gurnari
• MDS in young patients: Yasmin Abaza
• Cohesin genes mutated MDS: Tariq Kewan

Panel discussion

• How to approach hypoplastic MDS: Emma Groarke
• Targeting splicing mutation mutated in MDS: Jan Bewersdorf
• How should TP53-mutated MDS be classified?: Bing Li
• Should TPO Mimetics be standard of care In thrombocytopenic LR-MDS: Anne Sophie Kubasch

Panel discussion

Session 3: New directions and governmental progress
Chairs: Valeria Santini & Elizabeth Griffiths                                    

• Oral hypomethylating agents in MDS – what is next?: Elizabeth Griffiths
• Impact of responses to HMAs in context of baseline Genetic risk and Transplant: a VALIDATE icMDS analysis: Maximilian Stahl
• Overview of the NIH Program for MDS: Alain Mina
• Overview of CTEP/NCI efforts for MDS: Olatoyosi Odenike
• Improving Governmental-Academic collaborations for better MDS research: Steven Gore

Panel discussion

Lunch

Session 4: Inflammation and immune interventions
Chairs: Andrew Wei & Rena Buckstein                                                                                                  

• IRAK inhibitors in MDS and AML: Uwe Platzbecker
• STAT3 targeting in MDS: Aditi Shastri
• Immune checkpoint use in MDS/AML-a dead end?: Amer Zeidan

Panel discussion

Session 5: Classification and risk stratification updates
Chairs: Maria Teresa Voso & Olatoyosi Odenike

• Roadmap for harmonization of classifications: Somedeb Ball
• Prognosis assessment in resource-limited countries: Maria Teresa Voso
• Predicting relapse risk in MDS post-transplant: Ready for primetime?: Christopher Hourigan
• The Role of Classification versus Prognostication in MDS Patients: Robert Hasserjian
• Towards uniform and inclusive patient eligibility criteria for MDS clinical trials: Uma Borate

Panel discussion

Break

Keynote talk – Proceedings from FDA/NCI workshop on drug development in MDS: Nina Kim
Chairs: Amer Zeidan & Michael Savona

Panel discussion – Kelly Norsworthy, David Steensma, Steven Gore, Valeria Santini

Recognition awards

Wrap up of Day 2

Session 6: Response assessment & regulatory considerations
Chairs: Amer Zeidan & Nina Kim  

• How can we measure disease modification in LR-MDS: Rami Komrokji
• How should MDS-IB2 (AML/MDS) be approached in clinic and trials? Katharina Götze
• Do we still need to do bone marrow evaluations to diagnose, risk stratify and evaluate for response in MDS? Lisa Pleyer
• MRD negative CR as an endpoint in MDS: Arjan van de Loosdrecht
• IWG response criteria evolution for higher-risk MDS: Andrew Brunner

Panel discussion

Session 7: TP53 aberrations and Secondary AML
Chairs: Valeria Santini & Andrew Wei 

• How to use TP53 status for clinical decisions in MDS?: Coleman Lindsley
• Therapies for secondary AML: Thomas Cluzeau
• Targeting the CD47-SIRPa axis in MDS/AML: David Sallman
• Putting it together: current and future perspectives in TP53 mutated AML: Andrew Wei

Panel discussion

Break

Session 8: Advances in LR-MDS therapies
Chairs: Uwe Platzbecker & Valeria Santini     

• Telomerase inhibition: Uwe Platzbecker
• TGF pathway modulation: Amer Zeidan
• Is roxadustat and HIF targeting in MDS still a viable approach?: Valeria Santini
• Putting it together – how do I manage LR-MDS in 2023: Hetty Carraway

Panel discussion

Lunch

Session 9: Updates in HR-MDS therapies
Chairs: Andrew Wei & Amer Zeidan

• IDH inhibitors- mono or combination therapy in MDS?: Marie Sebert
• RARA agonists- Updates in use of RARA agonists in MDS?: Amy DeZern
• Venetoclax in HR-MDS – SOC or not?: Yazan Madanat
• Do selectin inhibitors have potential role in HR-MDS/AML?: Gail Roboz
• Putting it all together – New directions in management of HR-MDS: Andrew Wei

Panel discussion

Session 10: Big data and quality of life measures
Chairs: Rena Buckstein & Mikkael Sekeres

• Evolving role of artificial intelligence for MDS prognostication: Adrián Mosquera Orgueira
• Clinical characteristics of MDS using registration data in Japan: Yasushi Miyazaki
• QoL assessment in MDS in trials and clinical practice – the icMDS recommendations: Fabio Efficace
• Using real world data and quality of life as meaningful enpoints in trials: Mikkael Sekeres

Panel discussion

End of meeting summary